John M Baer

6PUBLICATIONS
71CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 24, 2025
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.

Patrick M Grierson, Crystal Wolf, Rama Suresh

|Apr 29, 2024
Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression.

Jiayu Ye, John M Baer, Douglas V Faget

|Apr 29, 2024
Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer.

Jad I Belle, Devashish Sen, John M Baer

|May 25, 2023
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer.

C Alston James, John M Baer, Chong Zou

|Mar 23, 2023
Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy.

Chong Zuo, John M Baer, Brett L Knolhoff

|Sep 27, 2022
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade.

Varintra E Lander, Jad I Belle, Natalie L Kingston

Pageof 1

Frequent Collaborators

6 joint publications

David G DeNardo

4 joint publications

Varintra E Lander

4 joint publications

Jad I Belle

4 joint publications

Brett L Knolhoff